# Arktus Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/arktus-therapeutics

- Industry: Biotechnology
- Headquarters: Kyoto-shi, Japan
- Website: www.arktustx.com
- Total disclosed funding: $2.9M
- Latest round: Series A (Sep 22, 2025)
- Investors on record: 9

## About

Based in Kyoto, Japan, and founded in 2023 by Chief Executive Officer Tomohiro Oiwa, based in Japan, Arktus Therapeutics Inc. operates as a medicine research and development company providing regenerative therapies to create new knee cartilages from stem cells. In September 2025,? Arktus Therapeutics Inc. raised an undisclosed amount ?in?series A funding? from new investors Chushin Venture Capital and Regional, Talent and Future, with participation from returning investors Kyoto University Innovation Capital, Kyoto Capital Partners, QB Capital, Investment Lab, Sagin Capital & Consulting, and Japan Science and Technology Agency.

Arktus Therapeutics Inc. specializes in knee cartilage regeneration medicine using a unique combination of iPS cells and chondrocyte 3D printing technology. This groundbreaking approach addresses the increasing prevalence of knee pain and osteoarthritis by offering a treatment option that surpasses the limitations of conventional methods. By harnessing the patient's own cells, Arktus Therapeutics Inc. enables the restoration of natural movement and function of the knee joint, leading to more effective and personalized recovery outcomes. Their core technologies, including the induction of mesenchymal stem cells from iPS cells and bio-3D printing of chondrocytes, represent significant advancements in the field of regenerative medicine, promising a brighter future for individuals seeking relief from knee-related ailments.

The company plans to use its proceeds from September 2025 funding to carry out non-clinical trials in accordance with GLP standards for its scaffold-free cartilage implant developed using induced pluripotent stem cells

## Funding rounds

- Series A, Sep 22, 2025 — Sagin Capital & Consulting, Japan Science and Technology Agency, Chushin Venture Capital, Kyoto University Innovation Capital, QB Capital, Kyoto Capital Partners, Investment Lab(VC), Regional, Talent and Future
- Seed, Apr 10, 2024, $2.9M — Sagin Capital & Consulting, Japan Science and Technology Agency, Kyoto University Innovation Capital, QB Capital, Kyoto Capital Partners, MTG Ventures, Investment Lab(VC)

## Investors

- Sagin Capital & Consulting (https://capitalatlas.ai/funds/sagin-capital-consulting) — Seed, Series A
- Japan Science and Technology Agency — Seed, Series A
- Kyoto University Innovation Capital (https://capitalatlas.ai/funds/kyoto-university-innovation-capital) — Seed, Series A
- QB Capital (https://capitalatlas.ai/funds/qb-capital) — Seed, Series A
- Kyoto Capital Partners (https://capitalatlas.ai/funds/kyoto-capital-partners) — Seed, Series A
- MTG Ventures (https://capitalatlas.ai/funds/mtg-ventures) — Seed
- Investment Lab(VC) — Seed, Series A
- Chushin Venture Capital (https://capitalatlas.ai/funds/chushin-venture-capital) — Series A
- Regional, Talent and Future (https://capitalatlas.ai/funds/regional-talent-and-future) — Series A